TY - JOUR
T1 - An Update on the Pathogenesis and Treatment of Chronic Recurrent Multifocal Osteomyelitis in Children
AU - Taddio, Andrea
AU - Taddio, Andrea
AU - Zennaro, Floriana
AU - Pastore, Serena
AU - Cimaz, Rolando
PY - 2017/6/1
Y1 - 2017/6/1
N2 - © 2017, Springer International Publishing Switzerland. Chronic recurrent multifocal osteomyelitis (CRMO), also known as chronic non-bacterial osteomyelitis (CNO), is a rare inflammatory disorder that primarily affects children. It is characterized by pain, local bone expansion, and radiological findings suggestive of osteomyelitis, usually at multiple sites. CRMO predominantly affects the metaphyses of long bones, but involvement of the clavicle or mandible are suggestive of the diagnosis. CRMO is a diagnosis of exclusion, and its pathogenesis remains unknown. Differential diagnosis includes infection, malignancies, benign bone tumors, metabolic disorders, and other autoinflammatory disorders. Biopsy of the bone lesion is not often required but could be necessary in unclear cases, especially for differentiation from bone neoplasia. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment. Alternative therapies have been used, including corticosteroids, methotrexate, bisphosphonates, and tumor necrosis factor (TNF)-α inhibitors. No guidelines have been established regarding diagnosis and treatment options. This manuscript gives an overview of the most recent findings on the pathogenesis of CRMO and clinical approaches for patients with the condition.
AB - © 2017, Springer International Publishing Switzerland. Chronic recurrent multifocal osteomyelitis (CRMO), also known as chronic non-bacterial osteomyelitis (CNO), is a rare inflammatory disorder that primarily affects children. It is characterized by pain, local bone expansion, and radiological findings suggestive of osteomyelitis, usually at multiple sites. CRMO predominantly affects the metaphyses of long bones, but involvement of the clavicle or mandible are suggestive of the diagnosis. CRMO is a diagnosis of exclusion, and its pathogenesis remains unknown. Differential diagnosis includes infection, malignancies, benign bone tumors, metabolic disorders, and other autoinflammatory disorders. Biopsy of the bone lesion is not often required but could be necessary in unclear cases, especially for differentiation from bone neoplasia. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment. Alternative therapies have been used, including corticosteroids, methotrexate, bisphosphonates, and tumor necrosis factor (TNF)-α inhibitors. No guidelines have been established regarding diagnosis and treatment options. This manuscript gives an overview of the most recent findings on the pathogenesis of CRMO and clinical approaches for patients with the condition.
UR - http://www.scopus.com/inward/record.url?scp=85017454960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017454960&partnerID=8YFLogxK
U2 - 10.1007/s40272-017-0226-4
DO - 10.1007/s40272-017-0226-4
M3 - Article
C2 - 28401420
AN - SCOPUS:85017454960
VL - 19
SP - 165
EP - 172
JO - Paediatric Drugs
JF - Paediatric Drugs
SN - 1174-5878
IS - 3
ER -